Immunomedics, Inc. (IMMU) Develops Dendritic-Cell Vaccine Technology for Lymphomas and Leukemias
10/23/2013 9:49:21 AM
MORRIS PLAINS, N.J., Oct. 22, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced the issuance of U.S. patent no. 8,562,988 to its majority-owned subsidiary, IBC Pharmaceuticals, Inc. (IBC), for "Novel Strategies for Improved Cancer Vaccines."
Help employers find you! Check out all the jobs and post your resume.
comments powered by